Bispecifics vs CAR T-Cell Therapy: Which Is Better in Relapsed/Refractory Multiple Myeloma?
October 1st 2022Chimeric antigen receptor T-cell therapy is one such newer class of therapy to be introduced into the treatment paradigm for multiple myeloma, and bispecific antibodies are the expected next class of treatments to emerge in the clinic.
Read More
Immune Checkpoint Inhibitors and Novel Agents Are Explored in Hodgkin Lymphoma
September 30th 2022As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Read More
Should Small Molecules Be Sequenced or Administered in Combination Regimens in CLL?
September 30th 2022During a debate a the SOHO 2022 Annual Meeting, Jennifer R Brown, MD, PhD presented in favor of combining small molecules in CLL. Making the argument for sequencing small molecules in CLL was Anthony Mato, MD.
Read More
CAR T-Cell Therapy Could Replace Auto Transplant in Multiple Myeloma
September 30th 2022The depth and durability of responses seen with these CAR T-cell therapies in refractory myeloma is unprecedented and raises again the question of the role of up-front autologous stem cell transplant in the era of immune therapies, including CAR T-cell therapies.
Read More
In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy?
September 29th 2022With two recently approved chimeric antigen receptor T therapies targeting B-cell maturation antigen, this novel platform has altered the treatment paradigm for heavily-pretreated patients with multiple myeloma.
Read More
Ivosidenib Plus Azacitidine Improves Survival and Responses in IDH1-Mutated AML
September 29th 2022Results from the phase 3 AGILE study presented at SOHO 2022 show that ivosidenib plus azacitidine prolong event-free and overall survival with good responses vs placebo in patients with IDH1-mutated acute myeloid leukemia
Read More